昊海生科(688366)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
民生证券 2024-04-17 买入
天风证券 2024-04-10 买入
国盛证券 2024-03-12 买入 买入
东北证券 2024-03-12 增持
东吴证券 2024-03-11 买入
广发证券 2024-03-11 买入 买入
  盈利预测
据昊海生科一季报分析:

  盈利能力维持稳定,主营业务利润贡献明显提升

  成长能力维持稳定,净利增速明显收缩,削弱成长潜力

  偿债能力维持稳定,负债资产占比维持稳定

  运营能力维持稳定,应收账款周转速度需加快

  现金流能力有所削弱,可持续经营能力转向恶化

  财务数据
    截至2024年第一季度实现净利润0.92亿元,每股收益0.58元。

    截至2024年第一季度最新股东权益612223.21万元,未分配利润282932.62万元。

    截至2024年第一季度最新总资产719295.28万元,负债107072.07万元。

利润表
报告期2024-03-312023-12-312023-09-302023-06-30
营业总收入645,995,271.222,654,039,068.791,981,789,458.111,312,902,451.62
营业总成本535,026,579.062,187,742,639.371,616,376,970.691,075,921,430.82
营业利润114,427,839.61507,413,312.5388,603,227.42248,632,839.83
利润总额114,164,988.83508,260,726.21389,349,352.39249,797,428.33
净利润92,488,777.12412,269,260.17326,967,441.02208,687,100.06
其他综合收益-21,216,593.79-7,832,385.98-2,992,987.8740,876,316.38
综合收益总额71,272,183.33404,436,874.19323,974,453.15249,563,416.44
资产负债表
报告期2024-03-312023-12-312023-09-302023-06-30
流动资产合计3,745,333,949.093,750,143,782.753,715,795,672.923,878,569,755.92
非流动资产合计3,447,618,873.853,355,353,168.43,373,630,857.823,375,598,403.31
资产总计7,192,952,822.947,105,496,951.157,089,426,530.747,254,168,159.23
流动负债合计689,765,433.57715,951,389.68580,055,876.42657,787,506.67
非流动负债合计380,955,248.44372,252,588.29431,012,686.44505,809,020.53
负债合计1,070,720,682.011,088,203,977.971,011,068,562.861,163,596,527.2
归属于母公司股东权益合计5,755,069,480.725,650,064,203.235,704,966,947.125,709,617,329.58
股东权益合计6,122,232,140.936,017,292,973.186,078,357,967.886,090,571,632.03
负债和股东权益合计7,192,952,822.947,105,496,951.157,089,426,530.747,254,168,159.23
现金流量表
报告期2024-03-312023-12-312023-09-302023-06-30
经营活动现金流入小计705,232,753.892,966,731,428.162,202,212,262.841,467,437,782.25
经营活动现金流出小计629,263,051.252,332,282,032.331,810,647,919.361,183,466,418.03
经营活动产生的现金流量净额75,969,702.64634,449,395.83391,564,343.48283,971,364.22
投资活动现金流入小计1,140,250,242.381,213,341,353.591,089,423,627.13718,981,754.53
投资活动现金流出小计980,959,794.611,589,990,041.921,487,246,691.67974,622,221.68
投资活动产生的现金流量净额159,290,447.77-376,648,688.33-397,823,064.54-255,640,467.15
筹资活动现金流入小计84,864,109.94434,573,553.38329,686,285.31235,163,480.78
筹资活动现金流出小计42,726,434.75692,300,302.25487,575,027.29187,541,423.1
筹资活动产生的现金流量净额42,137,675.19-257,726,748.87-157,888,741.9847,622,057.68
汇率变动对现金及现金等价物的影响-524,411.4210,047,47011,313,076.0216,514,567.72
现金及现金等价物净增加额276,873,414.1810,121,428.63-152,834,387.0292,467,522.47
期末现金及现金等价物余额846,192,318.84569,318,904.66406,363,089.01651,664,998.5
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点

    截至2024年第一季度实现净利润0.92亿元,每股收益0.58元。

    截至2024年第一季度最新股东权益612223.21万元,未分配利润282932.62万元。

    截至2024年第一季度最新总资产719295.28万元,负债107072.07万元。

利润表
报告期2024-03-312023-12-312023-09-302023-06-30
营业总收入645,995,271.222,654,039,068.791,981,789,458.111,312,902,451.62
营业总成本535,026,579.062,187,742,639.371,616,376,970.691,075,921,430.82
营业利润114,427,839.61507,413,312.5388,603,227.42248,632,839.83
利润总额114,164,988.83508,260,726.21389,349,352.39249,797,428.33
净利润92,488,777.12412,269,260.17326,967,441.02208,687,100.06
其他综合收益-21,216,593.79-7,832,385.98-2,992,987.8740,876,316.38
综合收益总额71,272,183.33404,436,874.19323,974,453.15249,563,416.44
资产负债表
报告期2024-03-312023-12-312023-09-302023-06-30
流动资产合计3,745,333,949.093,750,143,782.753,715,795,672.923,878,569,755.92
非流动资产合计3,447,618,873.853,355,353,168.43,373,630,857.823,375,598,403.31
资产总计7,192,952,822.947,105,496,951.157,089,426,530.747,254,168,159.23
流动负债合计689,765,433.57715,951,389.68580,055,876.42657,787,506.67
非流动负债合计380,955,248.44372,252,588.29431,012,686.44505,809,020.53
负债合计1,070,720,682.011,088,203,977.971,011,068,562.861,163,596,527.2
归属于母公司股东权益合计5,755,069,480.725,650,064,203.235,704,966,947.125,709,617,329.58
股东权益合计6,122,232,140.936,017,292,973.186,078,357,967.886,090,571,632.03
负债和股东权益合计7,192,952,822.947,105,496,951.157,089,426,530.747,254,168,159.23
现金流量表
报告期2024-03-312023-12-312023-09-302023-06-30
经营活动现金流入小计705,232,753.892,966,731,428.162,202,212,262.841,467,437,782.25
经营活动现金流出小计629,263,051.252,332,282,032.331,810,647,919.361,183,466,418.03
经营活动产生的现金流量净额75,969,702.64634,449,395.83391,564,343.48283,971,364.22
投资活动现金流入小计1,140,250,242.381,213,341,353.591,089,423,627.13718,981,754.53
投资活动现金流出小计980,959,794.611,589,990,041.921,487,246,691.67974,622,221.68
投资活动产生的现金流量净额159,290,447.77-376,648,688.33-397,823,064.54-255,640,467.15
筹资活动现金流入小计84,864,109.94434,573,553.38329,686,285.31235,163,480.78
筹资活动现金流出小计42,726,434.75692,300,302.25487,575,027.29187,541,423.1
筹资活动产生的现金流量净额42,137,675.19-257,726,748.87-157,888,741.9847,622,057.68
汇率变动对现金及现金等价物的影响-524,411.4210,047,47011,313,076.0216,514,567.72
现金及现金等价物净增加额276,873,414.1810,121,428.63-152,834,387.0292,467,522.47
期末现金及现金等价物余额846,192,318.84569,318,904.66406,363,089.01651,664,998.5
  十大流通股东
十大流通股东 报告期:2024-03-31
股东名称 持股数量(万股) 占总股本比例(%) 上期持股变化(万股)
蒋伟4752.0028.17307.10
香港中央结算(代理人)有限公司2952.3617.50-329.64
游捷2880.0017.070.00
楼国梁615.123.650.00
吴剑英606.843.603.44
侯永泰600.633.560.00
彭锦华283.001.680.00
刘远中200.001.190.00
王文斌171.951.02171.95
  主力控盘
  公司简介
昊海生科 所属地域: 上海市 涉及概念: 沪股通,医美概念,眼科医疗,融资融券
主营业务: 基因工程、化学合成、天然药物、诊断试剂内的技术开发、技术转让、技术咨询、技术服务;小容量注射剂、原料药、生物工程产品、Ⅲ类6822植入体内或长期接触体内的眼科光学器具、6864可吸收性止血、防粘连材料的研究、生产;从事货物及技术的进出口业务,医疗器械的经营,乙醇(无水)的批发(租用存储设施),化工原料及产品(除危险化学品)、化妆品的销售。
上市日期: 2019-10-30 每股净资产: 34.11元 每股收益: 0.58元 净利润: 0.98亿元 净利润增长率: 20.16%
营业收入: 6.46亿元 每股现金流: 0.45元 每股公积金: 17.21元 每股未分配利润: 16.77元 总股本: 1.69亿 流通股: 1.39亿
以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心